Effect of Brimonidine on Corneal Thickness

Augenarztpraxis Breisach

Status: Unknown

Conditions: Impact of Brimonidine on the Cornea

Treatments: Drug: brimonidine 0.1%; Drug: placebo

Study type: Observational

Funder types: Other

Identifiers

NCT01250236

Grueb Klin CT

Details and patient eligibility

About

Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study

Exclusion criteria

• any serious medical or neurologic conditions and/or regular use of local or systemic medications

Trial design

10 participants in 2 patient groups

verum

Description:

brimonidine 0.1% eye drops twice daily

Treatment:

Drug: brimonidine 0.1%

placebo

Description:

sodium hyaluronate 1.8mg/ml eye drops twice daily

Treatment:

Drug: placebo